All in all, a principle framework that integrates multi-omics insights and incorporates rigorous evaluation of canonical targets such as p53 and Caspase-3 will be essential to systematically identify optimal targets for siRNA-based therapies in AKI. Here, CASP3 is linked to acute kidney injury.